1357002-32-4

Upstream product

• 6294-89-9 hydrazinecarboxylic acid methyl ester 
• 94-99-5 2,4-Dichlorobenzyl chloride 

Downstream Products

• 888738-82-7 methyl 1-(2,4-dichlorobenzyl)-3-hydroxy-1H-pyrazole-5-carboxylate 
• 1357002-36-8 4-[3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]butanenitrile 
• 1357002-35-7 3-[3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]propan-1-ol 
• 1357002-34-6 [3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]acetonitrile 
• 926296-66-4 [3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]methanol 
• 926296-65-3 methyl 3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazole-5-carboxylate 
• 926299-70-9 (E)-3-[1-(2,4-dichlorobenzyl)-3-isopropoxy-1H-pyrazol-5-yl]-N-(pentylsulfonyl)propenamide 
• 888738-57-6 ethyl (E)-3-[1-(2,4-dichlorobenzyl)-3-isopropoxy-1H-pyrazol-5-yl]propenoate 
• 926296-24-4 ethyl (E)-3-[1-(2,4-dichlorobenzyl)-3-hydroxy-1H-pyrazol-5-yl]propenoate 
• 926296-20-0 3-[1-(2,4-dichlorobenzyl)-3-(pyridin-2-ylmethoxy)-1H-pyrazol-5-yl]propanoic acid 
• 926299-79-8 3-[3-(benzyloxy)-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]-N-(pentylsulfonyl)propanamide 
• 926299-78-7 3-[1-(2,4-dichlorobenzyl)-3-(2-methoxyethoxy)-1H-pyrazol-5-yl]-N-(pentylsulfonyl)propanamide 
• 926299-73-2 3-[3-butoxy-1-(2,4-dichlorobenzyl)-1H-pyrazol-5-yl]-N-(pentylsulfonyl)propanamide 
• 926296-19-7 ethyl 3-[1-(2,4-dichlorobenzyl)-3-(pyridin-2-ylmethoxy)-1H-pyrazol-5-yl]propanoate 

Relevant academic research and scientific papers

A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides

Herein, we describe the design, synthesis, and structure-activity relationships of novel benzylpyrazole acylsulfonamides as non-thiazolidinedione (TZD), non-carboxylic-acid-based peroxisome proliferator-activated receptor (PPAR) γ agonists. Docking model analysis of in-house weak agonist 2 bound to the reported PPARγ ligand binding domain suggested that modification of the carboxylic acid of 2 would help strengthen the interaction of 2 with the TZD pocket and afford non-carboxylic-acid-based agonists. In this study, we used an acylsulfonamide group as the ring-opening analog of TZD as an isosteric replacement of carboxylic acid moiety of 2; further, preliminary modification of the terminal alkyl chain on the sulfonyl group gave the lead compound 3c. Subsequent optimization of the resulting compound gave the potent agonists 25c, 30b, and 30c with high metabolic stability and significant antidiabetic activity. Further, we have described the difference in binding mode of the carboxylic-acid-based agonist 1 and acylsulfonamide 3d.

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the general formula (I): [wherein Ar represents an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1, and Z2 each represents a bond, O, S, -CO-, -CS-, -CR3(OR4)-, -NR5-, -SO-, -SO2-, -CONR6-, or -NR6CO- (R3, R4, R5, and R6 are as defined in the description); Xb and Yb each represents a bond or a C1-20 divalent hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; ring A represents an aromatic ring (other than benzimidazole) which may be further substituted; n is an integer of 1-8; ring B represents an aromatic ring (other than oxazole) which may be further substituted; W represents a C1-20 divalent saturated hydrocarbon group; and R2 represents -OR8 or -NR9R10 (R8, R9, and R10 are as defined in the description)] or a salt of the compound. It is useful as a preventive/therapeutic agent for diabetes, etc.